Treatment and prophylaxis of recurrent genital herpes using vaccinia immunostimulant (Antiherpin).
192 patients, 72 women and 120 men, aged 18-75, presenting genital herpes, were followed. Among these, 122 formed the test batch, exclusively with Antiherpin, and 70 represented the control batch, treated with other therapeutic preparations. Antiherpin was administered by percutaneous route, by scarification. The following results were obtained: in the test batch 68.02% recoveries, 30.33% improvements and 1.64% statu quo; in the control batch no recoveries were recorded: only 60% statu quo but also 40% aggravations. However, after Antiherpin treatment beginning, even in this batch favourable results were obtained: in statu quo category, 66.7% recoveries, 30.9% improvements were obtained, 2.4% being not influenced by the treatment; in aggravation category 50% recoveries, 42.9% improvements were obtained, 7.1% maintaining their statu quo. During Antiherpin treatment, no case of adverse reaction was recorded, the preparation being very well tolerated by the organism. The above mentioned results prove Antiherpin efficacy in the treatment and prevention of genital herpes, even in the case of the patients previously being administered another treatment type.
Mihăilescu
R
R
Cantacuzino Institute, Bucharest, Romania.
Vitzu
M
M
Brestoiu
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000276:immunology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006558:Herpes Genitalis / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012995:Solubility; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D014765:Viral Vaccines; C074145:antiherpin